Provided by Tiger Fintech (Singapore) Pte. Ltd.

ZAI LAB

22.800
-0.300-1.30%
Volume:10.20M
Turnover:233.83M
Market Cap:25.10B
PE:-11.31
High:23.650
Open:22.900
Low:22.450
Close:23.100
Loading ...

BRIEF-Zai Lab Announces Acceptance Of Supplemental New Drug Application For Repotrectinib For Patients With NTRK-Positive Solid Tumors

Reuters
·
Yesterday

Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients With Ntrk-Positive Solid Tumors

THOMSON REUTERS
·
Yesterday

HK Movers|HK Pharma Stocks Shined. Zai Lab Up 15%; HBM Up 10%; Remegen Up 9%; Alphamab And Wuxi Bio Up 5%.

Tiger Newspress
·
14 Apr

Hong Kong Stocks Reverse Early Losses to End Higher; Pharma Stocks Slide

MT Newswires Live
·
09 Apr

Hong Kong Pharma Stocks Decline as Trump Threatens Tariffs on Imported Drugs

MT Newswires Live
·
09 Apr

BUZZ-HK-listed Zai Lab hits 2-year peak on higher product revenue

Reuters
·
28 Mar

Stock Track | Zai Lab Soars 5.23% as Annual Revenue Jumps Despite Net Loss

Stock Track
·
28 Mar

BRIEF-Zai Lab Posts FY Net Loss $257.1 Million

Reuters
·
28 Mar

Zai Lab - FY Net Product Revenue Increased to $397.6 Mln

THOMSON REUTERS
·
28 Mar

Zai Lab's Q4 2024 Net Loss Narrows; Revenue Beats Estimates

MT Newswires Live
·
28 Feb

Stock Track | Zai Lab Plummets 5.21% on Disappointing Q4 Earnings, Wider Loss

Stock Track
·
28 Feb

Zai Lab Ltd : Leerink Partners Raises Target Price to $74 From $72

THOMSON REUTERS
·
28 Feb

Zai Lab Ltd reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Feb

Zai Lab Ltd Outlook FY 2025 Total Revenue $560 Mln to $590 Mln

THOMSON REUTERS
·
27 Feb

Zai Lab Ltd - Q4 Total Revenues $109.1 Million

THOMSON REUTERS
·
27 Feb

Zai Lab Ltd expected to post a loss of 65 cents a share - Earnings Preview

Reuters
·
25 Feb

Zai Lab Receives Orphan Drug Designation From the U.S. FDA for Zl-1310 (Dll3 ADC) for the Treatment of Small Cell Lung Cancer (Sclc)

THOMSON REUTERS
·
23 Jan

BRIEF-Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia

Reuters
·
17 Jan

Zai Lab Announces Acceptance of New Drug Application for Karxt for the Treatment of Schizophrenia

THOMSON REUTERS
·
17 Jan

BRIEF-Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer

Reuters
·
15 Jan